PROSOMNUS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0337 USD | -15.11% |
|
-43.55% | -96.56% |
| May. 20 | ProSomnus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Motion for Joint Administration Filed by ProSomnus, Inc. | CI |
Financials (USD)
| Sales 2022 | 19.39M | Sales 2023 | 27.65M | Capitalization | 16.07M |
|---|---|---|---|---|---|
| Net income 2022 | -7M | Net income 2023 | -24M | EV / Sales 2022 | 5.49 x |
| Net Debt 2022 | 17.17M | Net Debt 2023 | 35.01M | EV / Sales 2023 | 1.85 x |
| P/E ratio 2022 |
-7.8
x | P/E ratio 2023 |
-0.66
x | Employees | 136 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProSomnus, Inc.
More recommendations
More press releases
| 1 day | -15.11% | ||
| 1 week | -43.55% | ||
| Current month | -66.30% | ||
| 1 month | -80.18% | ||
| 3 months | -93.67% | ||
| 6 months | -95.50% | ||
| Current year | -96.56% |
1 week
0.03
0.05
1 month
0.010.17
Current year
0.010.96
1 year
0.015.01
3 years
0.0111.30
5 years
0.0111.30
10 years
0.0111.30
| Managers | Title | Age | Since |
|---|---|---|---|
Leonard Liptak
FOU | Founder | 50 | 22-05-02 |
Sung Kim
FOU | Founder | 43 | 22-05-02 |
Brian Dow
DFI | Director of Finance/CFO | 55 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Johnson
BRD | Director/Board Member | 67 | 22-12-31 |
Leonard Hedge
BRD | Director/Board Member | 54 | - |
Steven Pacelli
BRD | Director/Board Member | 53 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 0.0337 | -15.11% | 29,124 |
| 24-05-22 | 0.0397 | +13.43% | 23,786 |
| 24-05-21 | 0.035 | +12.00% | 66,800 |
| 24-05-20 | 0.0312 | -30.71% | 211,175 |
| 24-05-17 | 0.0451 | -24.46% | 115,779 |
Delayed Quote OTC Markets, May 23, 2024 at 03:53 pm EDT
More quotes
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Companyâs products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -96.56% | 586K | |
| -17.75% | 2.74B | |
| -15.42% | 82.74M | |
| +7.25% | 51.22M |
- Stock Market
- Equities
- OSAPQ Stock
